Navigation Links
Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
Date:3/4/2009

---------------------- Revenue Rights revenue - - - 310,000 ------------------------------------------------------------------------- - - - 310,000 ------------------------------------------------------------------------- Expenses Research and development 13,351,875 12,385,743 11,378,998 74,531,777 Operating 4,311,575 3,826,195 3,630,144 24,837,025 Stock based compensation 64,039 539,156 403,550 4,768,844 Foreign exchange (gain) loss (68,283) 8,862 35,270 589,427 Amortization - intellectual property 361,500 361,500 361,500 3,434,250 Amortization - property and equipment 48,754 40,714 52,638 497,151 ------------------------------------------------------------------------- 18,069,460 17,162,170 15,862,100 108,658,474 ------------------------------------------------------------------------- Loss before the following 18,069,460 17,162,170 15,862,100 108,348,474 Interest income (519,256) (1,211,744) (1,233,809) (6,534,005) Gain on sale of BCY LifeSciences Inc. - - - (299,403) Loss on sale of Transition Therapeutics Inc. - - - 2,156,685 ------------------------------------------------------------------------- Loss before income taxes 17,550,204 15,950,426 14,628,291 103,671,751 Future income tax recovery - - - (1,115,000) ------------------------------------------------------------------------- Net lo
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... for various reagents used in the life ... driving the life science reagents market towards ... include manufacturers and providers of life science ... Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The ...
(Date:7/11/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the global ... nearly $140 billion in 2013. This is estimated to ... compound annual growth rate (CAGR) of 28.6%. , New ... and exciting possibilities within the broader PCR field. The ...
(Date:7/11/2014)... 11, 2014 Cayenne Medical, Inc., ... in the soft tissue reconstruction segment, announced the ... for surgeries involving the shoulder and extremities. The ... novel, inserter-controlled deployment method. The unique delivery eliminates ... anchor pull-out, or anchor displacement (also commonly know ...
(Date:7/10/2014)... July 10, 2014 Understanding the need ... cell lines, and the gap that currently exists in ... expand its industry-leading portfolio of validated ion channel and ... channel-expressing cell lines, as ion channels control many critical ... this activity creates the potential to treat a variety ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... WILMINGTON, N.C., Sept. 9 Wilmington Pharmaceuticals announced ... granted marketing approval for METOZOLV((TM)) ODT (metoclopramide HCl), an ... gastroesophageal reflux disease (GERD) and diabetic gastroparesis. Wilmington has ... pharmaceutical company with a focus on gastrointestinal disorders. , ...
... , SAN DIEGO, Sept. 9 Orexigen((R) )Therapeutics, Inc. ... obesity, today announced that the Company will be speaking at two upcoming investor ... , Morgan Stanley Global Healthcare Unplugged Conference, ... Time, Location: Grand Hyatt Hotel, New York, ...
... , , , , ... SAN FRANCISCO, Sept. 9 Medivation, Inc. (Nasdaq: MDVN ) ... the following conferences: , , , The ... Eastern Time at the Millennium Broadway Hotel in New York , ...
Cached Biology Technology:Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 2Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 3Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 4Medivation Announces Participation in Upcoming Conferences 2
(Date:7/11/2014)... new report from the Wildlife Conservation Society shows ... help economically valuable species such as lobster, conch, ... help re-colonize nearby reef areas. , The reporttitled ... systematic review of research literature from no-take areas ... Dr. Craig Dahlgren, a recognized expert in marine ...
(Date:7/11/2014)... July 11, 2014--Researchers at the Department of Energy,s ... 100 awards, presented by R&D Magazine in recognition ... "These awards recognize the tremendous value of our ... "Research and development at the National Labs continues ... and pursue the scientific and technological innovations necessary ...
(Date:7/11/2014)... many fires burning in eastern New South Wales, Australia ... , At 03:35 UTC on July 11 (12:35 p.m. ... passed over eastern New South Wales (NSW), the Moderate ... image of the region and spotted smoke (light brown) ... thermal bands, are outlined in red. , The New ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... In Nature, cells and tissues assemble and organize themselves ... their structure and function, such as the elasticity of ... design principles have now been successfully replicated in the ... Inspired Engineering and the School of Engineering and Applied ...
... ANN ARBOR, Mich. Why do some diseases ... the University of Michigan have found neural tissue contains ... susceptibility to a debilitating childhood movement disorder. ... and repetitive movements or abnormal postures. It,s caused by ...
... is an imposing bull always in search of the best ... 4 metres in length belongs to a group of 14 ... scientific assistants since recently. At the beginning of the Antarctic ... the mighty elephant seal bulls were tagged with state-of-the-art satellite ...
Cached Biology News:Harvard's Wyss Institute uses nature's design principles to create specialized nanofabrics 2Harvard's Wyss Institute uses nature's design principles to create specialized nanofabrics 3Neural tissue contains imbalanced levels of proteins, U-M study finds 2Seal bulls in the service of science 2Seal bulls in the service of science 3